セッション

Novel stem cell-targeted therapy for multiple myeloma based on dual inhibition of EZH1/2

[演者] Makoto Nakagawa (中川 亮):1,2
[著者] Shuhei Fujita (藤田 修平):1, Daisuke Honma (本間 大輔):3, Kazushi Araki (荒木 一司):3, Tatsuya Inoue (井上 竜也):4, Ayako Kato (加藤 亜矢子):4, Koichiro Inaki (稲木 公一郎):4, Chisa Wada (和田 千佐):4, Yoshimasa Ono (小野 祥正):4, Yasuharu Nakashima (中島 康晴):2, Issay Kitabayashi (北林 一生):1
1:Hematological Malignancy, Natl. Cancer Ctr. Res. Inst., Tokyo, Japan, 2:Dept. of Orthop. Surg., Kyushu Univ., Fukuoka, Japan, 3:Oncol. Lab., Daiichi Sankyo, Tokyo, Japan, 4:Disc. Sci. & Tech. Dept., Daiichi Sankyo RD Novare, Tokyo, Japan

HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications

[演者] Takeshi Harada:1
[著者] Hiroto Ohguchi:1, Yohann Grondin:2, Shohei Kikuchi:1, Morihiko Sagawa:1, Yu-Tzu Tai:1, Ralph Mazitschek:3, Teru Hideshima:1, Kenneth C. Anderson:1
1:Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 2:Molecular and Integrative Physiological Sciences Program, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 3:Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA

Ribonucleotide reductase large subunit (RRM1) as a novel therapeutic target in multiple myeloma

[演者] Morihiko Sagawa (佐川 森彦):1,2
[著者] Hiroto Ohguchi (大口 裕人):1, Takeshi Harada (原田 武志):1, Mehmet K. Samur:3, Yu-Tzu Tai:1, Nikhil C. Munshi:1, Masahiro Kizaki (木崎 昌弘):2, Teru Hideshima (秀島 輝):1, Kenneth C. Anderson:1
1:Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 2:Department of Hematology, Saitama Medical Center, Saitama Medical University, 3:Department of Biostatics and Computational Biology, Dana-Farber Cancer Institute, Boston

Immunodulatory drug binding protein TP53RK is a novel therapeutic target in multiple myeloma

[演者] Teru Hideshima:1
[著者] Francesca Cottini:1, Yoshihisa Nozawa:2, Hyuk-Soo Seo:1, Hiroto Ohguchi:1, Mehmet K. Samur:1, Diana Cirstea:1, Naoya Mimura:1, Yoshikazu Iwasawa:2, Paul Richardson:1, Nikhil C. Munshi:1, Dharminder Chauhan:1, Walter Massefski:1, Teruhiro Utsugi:2, Sirano Dhe-Paganon:1, Kenneth C. Anderson:1
1:Dana-Farber Cancer Institute, Harvard Medical School, USA, 2:TAIHO Pharmaceutical Co., Ltd.

詳細検索